The Molecular Mechanism of Transforming Growth Factor-β Signaling for Intestinal Fibrosis: A Mini-Review

Inflammatory bowel disease is known as the most chronic inflammatory disorder in colon, which subsequently progresses to intestinal obstruction and fistula formation. Many studies to date for the treatment of IBD have been focused on inflammation. However, most of the anti-inflammatory agents do not...

Full description

Saved in:
Bibliographic Details
Main Authors: Sun-Mi Yun (Author), Seok-Ho Kim (Author), Eun-Hee Kim (Author)
Format: Book
Published: Frontiers Media S.A., 2019-02-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_c9a5bb2d50a94c7fb12dadaad92d0b0e
042 |a dc 
100 1 0 |a Sun-Mi Yun  |e author 
700 1 0 |a Seok-Ho Kim  |e author 
700 1 0 |a Eun-Hee Kim  |e author 
245 0 0 |a The Molecular Mechanism of Transforming Growth Factor-β Signaling for Intestinal Fibrosis: A Mini-Review 
260 |b Frontiers Media S.A.,   |c 2019-02-01T00:00:00Z. 
500 |a 1663-9812 
500 |a 10.3389/fphar.2019.00162 
520 |a Inflammatory bowel disease is known as the most chronic inflammatory disorder in colon, which subsequently progresses to intestinal obstruction and fistula formation. Many studies to date for the treatment of IBD have been focused on inflammation. However, most of the anti-inflammatory agents do not have anti-fibrotic effects and could not relieve intestinal stricture in IBD patients. Because preventing or reversing intestinal fibrosis in IBD is a major therapeutic target, we analyzed the papers focusing on TGF-β signaling in intestinal fibrosis. TGF-β is a good candidate to treat the intestinal fibrosis in IBD which involves TGF-β signaling pathway, EMT, EndMT, ECM, and other regulators. Understanding the mechanism involved in TGF-β signaling will contribute to the treatment and diagnosis of intestinal fibrosis occurring in IBD as well as the understanding of the molecular mechanisms underlying the pathogenesis. 
546 |a EN 
690 |a transforming growth factor-β 
690 |a inflammatory bowel disease 
690 |a intestinal fibrosis 
690 |a epithelial-to-mesenchymal transition 
690 |a endothelial-to-mesenchymal transition 
690 |a extracellular matrix 
690 |a Therapeutics. Pharmacology 
690 |a RM1-950 
655 7 |a article  |2 local 
786 0 |n Frontiers in Pharmacology, Vol 10 (2019) 
787 0 |n https://www.frontiersin.org/article/10.3389/fphar.2019.00162/full 
787 0 |n https://doaj.org/toc/1663-9812 
856 4 1 |u https://doaj.org/article/c9a5bb2d50a94c7fb12dadaad92d0b0e  |z Connect to this object online.